1. Glenmark Pharma shares gain 4% after HSBC upgrades to ‘buy’

Glenmark Pharma shares gain 4% after HSBC upgrades to ‘buy’

Glenmark Pharmaceuticals shares rallied as much as 4 per cent in the early trade on Monday after HSBC upgrades shares of the pharma company from 'hold' to 'buy'.

By: | New Delhi | Updated: February 1, 2016 4:12 PM
glenmark pharma, sensex

Glenmark Pharmaceuticals shares rallied as much as 4 per cent in the early trade on Monday after HSBC upgrades shares of the pharma company from ‘hold’ to ‘buy’. (Photo: PTI)

Glenmark Pharmaceuticals shares rallied as much as 4 per cent in the early trade on Monday after HSBC upgrades shares of the pharma company from ‘hold’ to ‘buy’.

At 10.18 am, shares of Glenmark Pharma were trading 4 per cent up at Rs 801.75. The scrip opened at Rs 780 and had touched a high and low of Rs 801.80 and Rs 774.30, respectively, in trade so far. The scrip later settled 2.86 per cent up at Rs 792.95.

In the past six months, shares of Glenmark Pharmaceuticals fell 33 per cent to Rs 770.90 on January 29. On the other hand, Sensex fell 5.37 per cent during the period. According to HSBC, all negatives are priced in and stock is trading 20 per cent cheaper to peers.

For the quarter ended December 2015, the company a consolidated posted net profit of Rs 169.95 crore, up 48.07 per cent, against Rs 114.77 crore in the corresponding quarter a year ago.

According to Religare, Glenmark Pharma’s Q3 earnings missed estimates by 11 per cent led by a revenue miss across key geographies and higher taxes. “While emerging markets currency issues may persist near term, we expect US business – with approvals of Ortho-tricylen Lo, Nitroglycerin and later the Zetia launch – to drive performance in the medium term. We pare FY17 and FY18 earnings estimates by 18 per cent and 13 per cent to reflect the weak quarter, higher tax rate and gradual debt reduction, but retain ‘Buy’ on favourable valuations with a new March 2017 target price of Rs 1,040 (from Rs 1,370).”

(With inputs from Reuters)

  1. No Comments.

Go to Top